Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06615752 | Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients | recruiting | Phase 1 / Phase 2 | 99 | Charles Drew University of Medicine and ScienceOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07236112 | Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer | active not recruiting | Phase 1 | 6 | C Ray TherapeuticsINDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06044857 | PSMA PET Response Guided SabR in High Risk Pca | recruiting | Phase 1 | 20 | University of Texas Southwestern Medical CenterOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06190899 | Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 54 | Celcuity IncINDUSTRY | 4 | Apr 13, 2026 | clinicaltrials |
| NCT07192120 | A Study of MHB048C in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT03361436 | Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery | active not recruiting | Phase 1 | 15 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06303713 | LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer | active not recruiting | Phase 1 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07054307 | MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma(MH-Penile-001) | recruiting | Phase 1 | 10 | Jiyan LiuOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07214961 | Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)(ARTISAN) | active not recruiting | Phase 1 | 80 | ARTBIO Inc.INDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04147806 | A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer(PROSINT) | active not recruiting | Phase 1 | 31 | Albert Einstein College of MedicineOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07259213 | A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC(RAD402) | recruiting | Phase 1 / Phase 2 | 73 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06193486 | Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC | recruiting | Phase 1 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03860272 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | active not recruiting | Phase 1 | 499 | Agenus Inc.INDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT06395519 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies(ERADIC8) | recruiting | Phase 1 / Phase 2 | 120 | 858 Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06705686 | Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer(PHAROS) | recruiting | Phase 1 | 40 | TechnoGenesys, Inc.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05245006 | PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer | active not recruiting | Phase 1 | 30 | Robert Flavell, MD, PhDOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05888532 | 64Cu-GRIP B in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 91 | Rahul AggarwalOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07468396 | A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer | not yet recruiting | Phase 1 | 65 | Gan & Lee Pharmaceuticals.INDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT03424850 | Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy | recruiting | Phase 1 / Phase 2 | 36 | Washington University School of MedicineOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07090148 | Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC | recruiting | Phase 1 | 14 | University of Wisconsin, MadisonOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07182279 | Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer | recruiting | Phase 1 / Phase 2 | 29 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06130995 | Relugolix + Enzalutamide Study in High-Risk Prostate Cancer | recruiting | Phase 1 | 46 | University of OklahomaOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05546268 | Study of Oral MRT-2359 in Selected Cancer Patients | active not recruiting | Phase 1 / Phase 2 | 174 | Monte Rosa Therapeutics, IncINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06237179 | Behavioral Exercise Training to Reduce Cardiovascular Disease Risk(EXTRA-PC) | recruiting | Phase 1 / Phase 2 | 60 | Virginia Commonwealth UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04943536 | Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer(BiolenRT) | active not recruiting | Phase 1 | 20 | Alessa Therapeutics Inc.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT02353819 | Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer | active not recruiting | Phase 1 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT03089203 | CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer | active not recruiting | Phase 1 | 23 | University of PennsylvaniaOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT06267729 | Study of AZD0754 in Participants With Metastatic Prostate Cancer(APOLLO) | recruiting | Phase 1 / Phase 2 | 60 | AstraZenecaINDUSTRY | 3 | Feb 23, 2026 | clinicaltrials |
| NCT05720130 | Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study). | recruiting | Phase 1 / Phase 2 | 100 | AdvanCell Pty LimitedINDUSTRY | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07423117 | A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy | not yet recruiting | Phase 1 | 102 | IntoCell, IncINDUSTRY | 0 | Feb 20, 2026 | clinicaltrials |
| NCT06450106 | Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy | recruiting | Phase 1 | 18 | SURGE TherapeuticsINDUSTRY | 2 | Feb 19, 2026 | clinicaltrials |
| NCT07339267 | A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer | recruiting | Phase 1 | 12 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation(GUARDIAN-101) | recruiting | Phase 1 | 90 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT04478279 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Sapience TherapeuticsINDUSTRY | 2 | Feb 9, 2026 | clinicaltrials |
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | active not recruiting | Phase 1 / Phase 2 | 143 | TransgeneINDUSTRY | 3 | Feb 5, 2026 | clinicaltrials |
| NCT04459273 | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers(FAPI PET RDRC) | active not recruiting | Phase 1 | 26 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06631521 | Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer | recruiting | Phase 1 | 30 | AdventHealthOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04729114 | A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | recruiting | Phase 1 | 174 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Feb 4, 2026 | clinicaltrials |
| NCT05864196 | Two Fraction Prostate SBRT With DIL SIB | recruiting | Phase 1 | 80 | NYU Langone HealthOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05968144 | Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness(ADRIAN) | active not recruiting | Phase 1 / Phase 2 | 30 | University of Maryland, BaltimoreOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT06636123 | GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy | recruiting | Phase 1 | 30 | Virginia Commonwealth UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07363382 | The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer | recruiting | Phase 1 / Phase 2 | 6 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07363486 | Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 9 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07358806 | Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 51 | Oscotec Inc.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06830850 | A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 1 | 25 | Atridia Pty Ltd.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 466 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07181473 | A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 200 | Phrontline BiopharmaINDUSTRY | 2 | Jan 12, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 15, 2026source: clinicaltrials